A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL)
subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy, NCT03406156
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
A study in previously untreated Chronic Lymphocytic Leukemia to evaluate alternate administration strategies for induction therapy (debulking) with obinutuzumab or obinutuzumab/bendamustine prior to combination therapy with obinutuzumab and venetoclax.
MORE DETAILS ON THIS TRIAL
17106 / NCT03406156 / Open 8-9-2018